Neos Therapeutics (NEOS) – Research Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Neos Therapeutics (NASDAQ: NEOS):

  • 3/24/2018 – Neos Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 3/23/2018 – Neos Therapeutics was given a new $20.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock. They wrote, “Neos held its Analyst Day on March 22-23, which included a dinner with management and Behavioral Medicine KOLs Dr. Brian Barash and Dr. Birgit Amann, a presentation, and a manufacturing facility tour.””
  • 3/22/2018 – Neos Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
  • 3/17/2018 – Neos Therapeutics was given a new $14.00 price target on by analysts at Wells Fargo. They now have a “buy” rating on the stock.
  • 3/15/2018 – Neos Therapeutics was given a new $20.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 3/10/2018 – Neos Therapeutics was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 2/17/2018 – Neos Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

NASDAQ:NEOS opened at $8.30 on Friday. Neos Therapeutics Inc has a 12-month low of $6.30 and a 12-month high of $13.15. The company has a debt-to-equity ratio of 7.47, a quick ratio of 1.84 and a current ratio of 2.20. The firm has a market capitalization of $245.02, a PE ratio of -3.10 and a beta of -0.20.

How to Become a New Pot Stock Millionaire

Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings results on Thursday, March 15th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.12. Neos Therapeutics had a negative return on equity of 437.92% and a negative net margin of 264.80%. The business had revenue of $7.79 million for the quarter, compared to analyst estimates of $9.30 million. analysts forecast that Neos Therapeutics Inc will post -1.53 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of NEOS. JPMorgan Chase & Co. bought a new position in shares of Neos Therapeutics in the 3rd quarter worth $120,000. Paloma Partners Management Co bought a new position in shares of Neos Therapeutics in the 4th quarter worth $125,000. MetLife Investment Advisors LLC bought a new position in shares of Neos Therapeutics in the 4th quarter worth $134,000. New York State Common Retirement Fund boosted its position in shares of Neos Therapeutics by 67.3% in the 3rd quarter. New York State Common Retirement Fund now owns 17,400 shares of the company’s stock worth $159,000 after purchasing an additional 7,000 shares during the last quarter. Finally, Brandywine Global Investment Management LLC bought a new position in shares of Neos Therapeutics in the 4th quarter worth $179,000. Institutional investors and hedge funds own 49.33% of the company’s stock.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Receive News & Ratings for Neos Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

ExclusiveCoin  Price Hits $1.22 on Exchanges
ExclusiveCoin Price Hits $1.22 on Exchanges
Comparing Marriott International  and Its Competitors
Comparing Marriott International and Its Competitors
Head to Head Comparison: Synaptics  & LightPath Technologies
Head to Head Comparison: Synaptics & LightPath Technologies
eBitcoin Price Reaches $0.16
eBitcoin Price Reaches $0.16
Social Price Reaches $0.48
Social Price Reaches $0.48
Momo Inc  Given Consensus Rating of “Buy” by Analysts
Momo Inc Given Consensus Rating of “Buy” by Analysts


Leave a Reply

© 2006-2018 Ticker Report. Google+.